Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome

Breast Cancer Research and Treatment

Volumn 113, Issue 2, 2009, Pages 307-313

  Shien, Tadahiko ^a   Shimizu, Chikako ^a   Seki, Kunihiko ^a   Shibata, Taro ^b   Hojo, Takashi ^a   Ando, Masashi ^a   Kohno, Tsutomu ^a   Katsumata, Noriyuki ^a   Akashi Tanaka, Sadako ^a   Kinoshita, Takayuki ^a   Fujiwara, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

Author keywords

Breast cancer; Chemotherapy; Neoadjuvant; Predictor; Response

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CHEVAILLER CLASSIFICATION SYSTEM; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; FEMALE; FISHER CLASSIFICATION SYSTEM; HUMAN; INTERMETHOD COMPARISON; JAPANESE BREAST CANCER SOCIETY CLASSIFICATION SYSTEM; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG MONITORING; ESTROGENS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; JAPAN; LYMPHATIC METASTASIS; MASTECTOMY; METHOTREXATE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PACLITAXEL; PROGESTERONE; PROGNOSIS; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 58149240114     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-9935-2     Document Type: Article

References (19)

1. B Fisher J Bryant N Wolmark 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685
2. MA Bollet B Sigal-Zafrani L Gambotti 2006 Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study Eur J Cancer 42 2286 2295
3. B Chevallier H Roche JP Olivier 1993 Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate Am J Clin Oncol 16 223 228
4. Japanese Breast Cancer Society 2005 General rules for clinical and pathological recording of breast cancer Breast Cancer 12 S12 S14
5. Committee for Production of Histopathological Criteria. Japanese Breast Cancer Society 2001 Histopathological criteria for assessment of therapeutic response in breast cancer Breast Cancer 8 1
6. T Petit M Wilt M Velten 2004 Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant Anthracycline-based chemotherapy Eur J Cancer 40 205 211
7. RJ Burcombe A Makris PI Richman 2005 Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant Anthracycline chemotherapy for operable breast cancer Br J Cancer 92 147 155
8. LG Estevez WJ Gradishar 2004 Evidence-based use of neoadjuvant Taxane in operable and inoperable breast cancer Clin Cancer Res 10 3249 3261
9. RL Jones SR Lakhani AE Ring 2006 Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma Br J Cancer 94 358 362
10. R. A Rajan Poniecka TL Smith 2004 Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response Cancer 100 1365 1373
11. KN Ogston ID Miller S Payne 2003 A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival Breast 12 320 327
12. HD Bear S Anderson RE Smith 2006 Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 24 1 9
13. JY Pierga E Mouret V Laurence 2003 Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer: the role of clinical response Eur J Cancer 39 1089 1096
14. S Amat C Abrial F Penault-Llorca 2005 High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer Breast Cancer Res Treat 94 255 263
15. P Chollet S Amat H Cure 2002 Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer Br J Cancer 86 1041 1046
16. GN Hortobagyi AU Buzdar SW Kau 1998 Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy Cancer 62 2507 2516
17. DA Cameron ED Anderson P Levack 1997 Primary systemic therapy for operable breast cancer-10-year survival data after chemotherapy and hormone therapy Br J Cancer 76 1099 1105
18. BP Coudert L Arnold L Moreau 2006 Pre-operative systemic (neo-adjuvant) therapy with Trastuzumab and docetaxel for HER2-overexpressing stage II or stage III breast cancer: results of a multicenter phase II trial Ann Oncol 17 409 419
19. JT Lenert G Vlastos NQ Mirza 1999 Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients An Surg Oncol 6 762 767